Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement

MJ Page, JE McKenzie, PM Bossuyt, I Boutron… - Journal of clinical …, 2021 - Elsevier
Objectives To describe the processes used to update the PRISMA 2009 statement for
reporting systematic reviews, present results of a survey conducted to inform the update …

[HTML][HTML] An overview of platform trials with a checklist for clinical readers

JJH Park, O Harari, L Dron, RT Lester… - Journal of clinical …, 2020 - Elsevier
Objectives The objective of the study was to outline key considerations for general clinical
readers when critically evaluating publications on platform trials and for researchers when …

The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an …

M Dimairo, P Pallmann, J Wason, S Todd, T Jaki… - bmj, 2020 - bmj.com
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without
compromising the validity of conclusions and it is essential to distinguish pre-planned from …

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo …

Y Wang, F Zhou, D Zhang, J Zhao, R Du, Y Hu… - Trials, 2020 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus
(later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China …

Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs

T Burnett, P Mozgunov, P Pallmann, SS Villar… - BMC medicine, 2020 - Springer
Adaptive designs for clinical trials permit alterations to a study in response to accumulating
data in order to make trials more flexible, ethical, and efficient. These benefits are achieved …

Efficient adaptive designs for clinical trials of interventions for COVID-19

N Stallard, L Hampson, N Benda… - Statistics in …, 2020 - Taylor & Francis
The COVID-19 pandemic has led to an unprecedented response in terms of clinical
research activity. An important part of this research has been focused on randomized …

Long-term health outcomes for patients with obstructive sleep apnea: placing the Agency for Healthcare Research and Quality report in context—a multisociety …

SP Patil, ME Billings, G Bourjeily, NA Collop… - Journal of Clinical …, 2024 - jcsm.aasm.org
This multisociety commentary critically examines the Agency for Healthcare Research and
Quality (AHRQ) final report and systematic review on long-term health outcomes in …

[HTML][HTML] Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements

R Tunn, I Boutron, AW Chan, GS Collins… - Journal of Clinical …, 2024 - Elsevier
Objectives To describe, and explain the rationale for, the methods used and decisions made
during development of the updated SPIRIT 2024 and CONSORT 2024 reporting guidelines …

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and …

AM Manyara, P Davies, D Stewart, CJ Weir, A Young… - BMJ open, 2022 - bmjopen.bmj.com
Introduction Randomised controlled trials (RCTs) may use surrogate endpoints as
substitutes and predictors of patient-relevant/participant-relevant final outcomes (eg …

Sample size in multistakeholder Delphi surveys: at what minimum sample size do replicability of results stabilize?

AM Manyara, A Purvis, O Ciani, GS Collins… - Journal of Clinical …, 2024 - Elsevier
Abstract Background and Objective The minimum sample size for multistakeholder Delphi
surveys remains understudied. Drawing from three large international multistakeholder …